CNTACentessa Pharmaceuticals plc

CNTA Stock Price, Valuation & Chart | Centessa Pharmaceuticals plc

Compare

$40.500+0.00 (+0.00%)

At close · 25 June 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology CNTA intrinsic value Is CNTA overvalued or undervalued

Overview Financials Dividends Ratios

CNTA Historical price chart

CNTA Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization6.27B

PE Ratio-22.63

EPS-1.79

Trading Volume0

Today's High/Low40.5/40.5

Dividend Yield93.83

52 Week High/Low40.56/12.78

Shares Outstanding154.73M

CNTA Financial Statement

CNTA Analyst ratings

CNTA Analysis & performance metrics

CNTA Company profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include…

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C…

CNTA Management team

Name

Position

Karen M. Anderson

Chief People Officer

Stephen J. Kanes M.D., Ph.D.

Chief Medical Officer

Saurabh Saha M.D., Ph.D.CEO

Chief Executive Officer & Director

Iqbal J. Hussain L.L.B.

General Counsel, Chief Compliance Officer & Corporate Secretary

Kristen K. Sheppard Esq., J.D.

Senior Vice President of Investor Relations & Corporate Communications

Mario Alberto Accardi Ph.D.

President of the Orexin Program

Tia L. BushCTO

Chief Technology & Quality Officer

John J. Crowley CPACFO

Chief Financial Officer and Principal Financial & Accounting Officer

Name

Position

Karen M. Anderson

Chief People Officer

Stephen J. Kanes M.D., Ph.D.

Chief Medical Officer

Saurabh Saha M.D., Ph.D.CEO

Chief Executive Officer & Director

Iqbal J. Hussain L.L.B.

General Counsel, Chief Compliance Officer & Corporate Secretary

Kristen K. Sheppard Esq., J.D.

Senior Vice President of Investor Relations & Corporate Communications

Mario Alberto Accardi Ph.D.

President of the Orexin Program

Tia L. BushCTO

Chief Technology & Quality Officer

John J. Crowley CPACFO

Chief Financial Officer and Principal Financial & Accounting Officer

Management Team

Karen M. Anderson

Chief People Officer

Stephen J. Kanes M.D., Ph.D.

Chief Medical Officer

Saurabh Saha M.D., Ph.D.CEO

Chief Executive Officer & Director

Iqbal J. Hussain L.L.B.

General Counsel, Chief Compliance Officer & Corporate Secretary

Kristen K. Sheppard Esq., J.D.

Senior Vice President of Investor Relations & Corporate Communications

Mario Alberto Accardi Ph.D.

President of the Orexin Program

Tia L. BushCTO

Chief Technology & Quality Officer

John J. Crowley CPACFO

Chief Financial Officer and Principal Financial & Accounting Officer

Management

Karen M. Anderson

Chief People Officer

Stephen J. Kanes M.D., Ph.D.

Chief Medical Officer

Saurabh Saha M.D., Ph.D.CEO

Chief Executive Officer & Director

Iqbal J. Hussain L.L.B.

General Counsel, Chief Compliance Officer & Corporate Secretary

Kristen K. Sheppard Esq., J.D.

Senior Vice President of Investor Relations & Corporate Communications

Mario Alberto Accardi Ph.D.

President of the Orexin Program

Tia L. BushCTO

Chief Technology & Quality Officer

John J. Crowley CPACFO

Chief Financial Officer and Principal Financial & Accounting Officer

Total 8 executives

CNTA Frequently asked questions

What is Centessa Pharmaceuticals plc (CNTA) Stock Price?

Current stock price of Centessa Pharmaceuticals plc (CNTA) stock is $40.500. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Centessa Pharmaceuticals plc (CNTA) stock is 0.

Last updated at 25 June 2026, 08:00 pm.

Why is the Centessa Pharmaceuticals plc (CNTA) stock price going up or down today?

The stock price of Centessa Pharmaceuticals plc (CNTA) can change with earnings, company news, and overall market sentiment. Centessa Pharmaceuticals plc operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Centessa Pharmaceuticals plc stock expensive at its current price?

Whether Centessa Pharmaceuticals plc looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CNTA on this page is -22.63. EPS on this page is -1.79. Compare those figures with peers and growth expectations before deciding if the current Centessa Pharmaceuticals plc price is justified.

How has the stock price of Centessa Pharmaceuticals plc (CNTA) performed historically?

Historical performance for Centessa Pharmaceuticals plc (CNTA) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CNTA reacted to past earnings and market events.

Should I buy Centessa Pharmaceuticals plc (CNTA) stock, at this price?

Buying Centessa Pharmaceuticals plc (CNTA) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.